Changes in magnesium metabolism, along with those in sodium, were investigated in 17 patients with Graves' disease (14 females and 3 males, mean ± SD, 44.8 ± 12.2 years) and their relationship to plasma levels of thyroid hormones were assessed before and after treatment. Each patient was studied in hyperthyroid state and euthyroid state after treatment with methimazole. Treatment with methimazole increased the magnesium concentration both in erythrocytes (2.00 ± 0.18 vs. 2.08 ± 0.24 mmol/l cells, P<0.05) and in serum (0.72 ± 0.12 vs. 0.84 ± 0.11 mmol/l, P<0.001) but both urinary output and fractional excretion of magnesium decreased significantly (P<0.05 and P<0.001, respectively). The erythrocyte sodium concentration decreased with treatment (10.7 ± 2.6 vs. 8.1 ± 1.1 mmol/l cells, P<0.001) but the serum sodium remained unchanged (140.9 ± 1.9 vs. 140.9 ± 2.1 mmol/l, NS). Urinary excretion of sodium also decreased with treatment (P
CITATION STYLE
Disashi, T., Iwaoka, T., Tnoue, J., Naomi, S., Fujimoto, Y., Umeda, T., & Tomita, K. (1996). Magnesium metabolism in hyperthyroidism. Endocrine Journal, 43(4), 397–402. https://doi.org/10.1507/endocrj.43.397
Mendeley helps you to discover research relevant for your work.